The biotech sector continues to be an innovation driver in 2025 across different worldwide deals with international capital. Although macroeconomic headwinds such as inflation, interest rates uncertainty, and geopolitical tensions have contributed to volatility in the biotech sector, there have been signs of resilience that can be largely attributed to scientific innovation, the high value of clinical validation, and investors who are interested in high returns.

Venture Capital Deals in Biotech

The most common early source of institutional financing of biotech startups is venture capital. Following long development periods and regulatory hurdles in biotech and in the large risk involved, VC transactions are designed incrementally. In 2024, biotech VC fundraising exceeded pre pandemic levels, with early stage rounds totaling $15.5 billion.

Seed and Pre Seed Rounds: These are early stage investments used to validate basic scientific hypotheses build a founding team, or develop initial lab prototypes. Funding at this stage is relatively small but high-risk.

Series A: Startups that show promising preclinical or early clinical data secure Series A rounds. The goal is to progress to human trials.

Series B and C: These are growth rounds used to expand clinical programs, hire talent, and prepare for regulatory submissions. Investors focus on companies with early human data. In May 2025 Pathos AI raised $365 million in a Series D round marking the largest biotech fundraising of the month. The funding will advance its clinical pipeline and further develop its oncology focused AI Foundation Model.

Late-Stage or Mega Rounds: In 2024 over 68 biotech startups raised rounds of $100 million or more mainly targeting immunotherapy, rare diseases, and AI powered biotech platforms.

Private Equity (PE) in Biotech

Private equity companies were always targeting more mature or revenue producing sectors but have moved into biotech through innovative deal making.

Growth Equity: PE funds invest in later stage biotech companies to help scale manufacturing, enter new markets, or prepare for IPOs.

Buyouts: PE firms take over the control of a biotechnical firm typically to restructure or fold it into a bigger portfolio. In 2024, Novo Holdings led a $16.5 billion buyout of CDMO Catalent to expand healthcare manufacturing capacity. In 2025, Retro Biosciences raised $1 billion, while Eikon Therapeutics secured one of the year’s largest biotech VC rounds.

Spinouts: Certain bigger pharma companies sell R&D to PE partners who, in turn, finance them as separate biotech spin-offs.

Mergers & Acquisitions (M&A) in Biotech

One of the most popular ways of exit in biotech is M&A. Major pharmaceutical companies often buy innovation startups to refill their pipelines particularly when patents expire.

Pipeline Expansion: Smaller biotechs with potential drug candidates at Phase II or even Phase III are frequently acquired by larger pharmaceutical firms.

Strategic Fit: Businesses seek to find synergies with regard to disease focus, technology platforms or geographic coverage. J&J is set to acquire CNS biotech Intra Cellular Therapies for $14.6 billion.

Talent Acquisition: Sometimes the motivation is to acquire expert teams rather than products.

However, M&A with Chinese biotechs remained robust, amounting to $31.5 billion in 2024, and $18 billion just in Q1 2025.

Initial Public Offerings (IPOs) in Biotech

Initial public offering represents an evolutionary step of biotech companies. IPOs unlock public capital, provide early investors liquidity, and raise marketplace visibility. Several firms like Symbiotec Pharmalab are preparing IPOs in 2025 with over $1B valuations reflecting renewed investor appetite for specialty therapeutics.

Most biotech IPOs occur after successful Phase II trials or in anticipation of FDA filings. By this stage companies typically need large capital injections for manufacturing or market launch.

Traditional IPO: The company hires underwriters (investment banks) to price and market the shares. This is the most common form in biotech.

SPAC (Special Purpose Acquisition Company): A quicker route to public markets through a merger with a blank check company. SPACs boomed in 2021 but declined sharply post 2022 due to regulatory scrutiny.

Direct Listing: Companies bypass underwriters and list shares directly on the exchange. Rare in biotech due to the need for capital infusion which direct listings don’t offer.

Dual Track Process: Firms pursue both M&A and IPO options simultaneously to maximize valuation and flexibility.

Conclusion

The biotech industry’s capital journey involves early stage VC funding, growth via PE, strategic M&A exits, and public listings through IPOs. Every step of funding is connected to the level of advancement of a company and its economic requirements. Although VC and M&A continue to be the leading funding and exit methods, IPOs are gradually picking up pace as the market mood stabilizes in the year 2025.